Karyopharm Therapeutics | KPTI - Debt


Karyopharm Therapeutics reported $299.23M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Abbott USD 13.86B 919M Dec/2025
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Incyte USD 39.43M 982K Mar/2026
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 49.34B 7.97B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 47B 11.62B Mar/2026
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 63.73B 231M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Takeda JPY 4.85T 208B Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
TG Therapeutics USD 253.71M 8.37M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Xencor USD 187.75M 118.48M Dec/2025